Stool DNA testing for cancer surveillance in inflammatory bowel disease: An early view

John B. Kisiel, David A. Ahlquist

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Patients with inflammatory bowel disease (IBD) are at increased risk for colorectal cancer (CRC). Despite weak supporting evidence, important logistic barriers and high cost, colonoscopy is currently the only recommended approach to CRC surveillance in patients with IBD. As such, there is imperative to explore alternative or complementary strategies with potential to improve the efficiency and effectiveness of surveillance in IBD. Given our increasing understanding of tumorigenesis in IBD and the accompanying cascade of molecular alterations, there is a strong rationale to pursue biomarker assays for this application. Stool-based DNA testing with advanced technology has been shown to be highly discriminatory for detection of sporadic colorectal cancer and advanced precancers. In early observations, stool DNA testing also shows promise for the accurate detection of IBD-associated colorectal neoplasms. These findings raise important clinical and translational questions about how to best evaluate and develop this technology, and devise clinical algorithms that will complement colonoscopy to improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)371-380
Number of pages10
JournalTherapeutic Advances in Gastroenterology
Issue number5
StatePublished - Sep 2013


  • DNA methylation
  • colorectal neoplasms
  • early detection of cancer
  • inflammatory bowel disease
  • stool DNA

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Stool DNA testing for cancer surveillance in inflammatory bowel disease: An early view'. Together they form a unique fingerprint.

Cite this